World Alzheimer’s Day: Neuroimaging and artificial intelligence offer new opportunities for patients

Qynapse is strongly committed to innovation in the field of neurodegenerative diseases, particularly Alzheimer’s. “By combining the latest advances in neuroimaging and artificial intelligence algorithms, our solutions represent powerful tools for the diagnosis, disease monitoring and patient care for Alzheimer’s disease.”

Qynapse releases new data demonstrating the value of QyScore® for the clinical assessment of Multiple Sclerosis (MS)

These results confirmed that the use of a normative database for the interpretation of brain volumetric analysis, such as the QyScore® normative database, can improve the individual assessment of brain neurodegeneration in RRMS patients in the clinical routine setting.

Qynapse sponsors the 8th joint ACTRIMS-ECTRIMS meeting – MSVirtual2020

Qynapse is excited to participate in MSVirtual2020 to share and discuss innovative and cutting-edge research in the field of Multiple Sclerosis (MS).